Insider · CIK 0001533228
J. Scott Garland
Files at ELVN (Enliven Therapeutics, Inc.), ALXO (ALX ONCOLOGY HOLDINGS INC). First filing Oct 5, 2026, latest Oct 5, 2026.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
ELVN: Enliven Therapeutics, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 54Moderate | Enliven Therapeutics, Inc. | $607k 13,000 shares | -100% | +205% from low-24% from high |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 1, 2026 | ELVN Enliven Therapeutics, Inc. | MOption exercise Common Stock | +13,000 | $15.47 | $201k | 13,000 | 6 d ago |
| Oct 1, 2026 | ELVN Enliven Therapeutics, Inc. | SOpen-market sale Common Stock | -13,000 | $46.67 | $607k | 0 | 6 d ago |
| Oct 1, 2026 | ELVN Enliven Therapeutics, Inc. | MOption exercise Stock Option (right to buy)derivative | -13,000 | $0.00 | $0 | 46,372 | 6 d ago |
| Jan 21, 2025 | ALXO ALX ONCOLOGY HOLDINGS INC | AGrant or award Common Stockderivative | +40,400 | $0.00 | $0 | 40,400 | Jan 23, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.